Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 41

Results For "license"

409 News Found

Zydus Cadila entity to sell its India focused animal health business to a consortium
News | May 13, 2021

Zydus Cadila entity to sell its India focused animal health business to a consortium

The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,


Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
News | May 13, 2021

Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India

The agreement will help ensure wider reach and access to patients in India


Natco receives emergency use approval for Baricitinib tablets
News | May 05, 2021

Natco receives emergency use approval for Baricitinib tablets

The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic


India to import 450,000 vials of Remdesivir
News | May 01, 2021

India to import 450,000 vials of Remdesivir

The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country


Johnson & Johnson single-shot COVID-19 vaccine granted emergency use listing by WHO
News | March 15, 2021

Johnson & Johnson single-shot COVID-19 vaccine granted emergency use listing by WHO

The vaccine was 85 percent effective in preventing severe disease across all regions.


AstraZeneca Pharma India receives approval for supplying Osimertinib in India
News | March 13, 2021

AstraZeneca Pharma India receives approval for supplying Osimertinib in India

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.


NATCO receives approval for Everolimus tablets for the US market
News | March 09, 2021

NATCO receives approval for Everolimus tablets for the US market

NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.


DSM secures victory in patent infringement litigation against Anhui Tiger
News | March 02, 2021

DSM secures victory in patent infringement litigation against Anhui Tiger

Tiger can no longer make an important biotin intermediate using a DSM patented process.


Bayer gearing up for 2021-2030 decade
News | January 16, 2021

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business